chufangao/CTO huggingface dataset:
Clinical trial NCT03535506: Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery
Official title: Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery
Acronym: WI223281
Sponsor: Georgetown University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: lack of accrual
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-08
Primary completion date: 2023-12-06
Completion date: 2023-12-06
Plan to share individual participant data: NO
Clinical trial NCT02687386: A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR
Official title: A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT (EEDVsMit) in Children With Recurrent / Refractory Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor (EGFR) (ECREST Study)
Acronym: ECREST
Sponsor: Sydney Children's Hospitals Network (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study medication no longer in production
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-02-08
Primary completion date: 2021-12-29
Completion date: 2021-12-29
Plan to share individual participant data: UNDECIDED
IPD sharing description: De-identified data is planned to be shared with EnGeneIC.
Clinical trial NCT03113968: ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
Official title: ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
Acronym: ELEKT-D
Sponsor: The Cleveland Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 403.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-07
Primary completion date: 2022-10-28
Completion date: 2022-11-17
Baseline population: Intention-to-treat population
Limitations and caveats: Our trial has several limitations. ECT was started with right unilateral placement and was then switched to bilateral placement in the event of inadequate response. The open-label design of our trial could have influenced response. Maintenance treatment was not studied. Other limitations of our trial include a lack of placebo, the flexibility of treatment methods, and a follow-up period during which the patients received treatment as presc
Plan to share individual participant data: NO
Clinical trial NCT04361552: Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
Official title: Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Study abandoned due to drug billing issues
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-07
Primary completion date: 2020-06-02
Completion date: 2020-06-02
Plan to share individual participant data: NO
IPD sharing description: Results of the trial and not individual patient data will be shared. The study protocol, consent, and investigator's brochure will be available. The statistical plan is incorporated into the protocol, along with inclusion and exclusion criteria.
Clinical trial NCT04667468: Cold Stored Platelet in Hemorrhagic Shock
Official title: Cold Stored Platelet Early Intervention in Hemorrhagic Shock (CriSP-HS) Trial
Acronym: CriSP-HS
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 200.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-21
Primary completion date: 2023-10-07
Completion date: 2023-11-20
Plan to share individual participant data: YES
IPD sharing description: De-identified data may be shared with the funding agency as well as other researchers upon request to the Principal Investigator.
IPD time frame: Data will become available after publication of the primary manuscript.
IPD access criteria: Requests for data will be submitted in writing and reviewed by the Principal Investigator.
Clinical trial NCT04487808: Diet Quality, Pecans, and Cardiometabolic Health
Official title: Cardiometabolic Effects of Including Pecans as a Snack in Dietary Patterns That Vary in Diet Quality: a Randomized, Controlled Feeding, Crossover Study
Sponsor: Penn State University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The study did not enroll any subjects. It was never started because of the Covid pandemic.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-05-01
Primary completion date: 2022-07-01
Completion date: 2022-07-01
Plan to share individual participant data: NO
Clinical trial NCT03989713: Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD
Official title: Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD
Acronym: Q-HAM
Sponsor: University Hospital Heidelberg (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study turned out no longer feasible
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-17
Primary completion date: 2022-09-11
Completion date: 2022-09-11
Clinical trial NCT03744637: A Study of Single Doses of MK -5475 on Pulmonary Vascular Resistance (MK-5475-002)
Official title: A Study to Assess the Effect of Single Doses of MK -5475 on Pulmonary Vascular Resistance in Patients With Moderate to Severe Pulmonary Arterial Hypertension
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-01-18
Primary completion date: 2020-12-11
Completion date: 2020-12-11
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT02291289: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
Official title: A Multi-Centre Randomised Clinical Trial of Biomarker-Driven Maintenance Treatment for First-Line Metastatic Colorectal Cancer (MODUL)
Acronym: MODUL
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 1044.0 (ACTUAL)
Number of arms: 13.0
Start date: 2015-04-17
Primary completion date: 2019-05-31
Completion date: 2021-03-24
Clinical trial NCT04696848: The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
Official title: A Phase I Study to Determine the Efficacy and Safety of CKD-516 Tablet Combined With Durvalumab(MEDI4736) in Patient Refractory Solid Tumors
Sponsor: Asan Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Recruitment difficulty
Enrollment: 25.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-24
Primary completion date: 2023-03-09
Completion date: 2023-03-09
Plan to share individual participant data: NO
Clinical trial NCT03554161: Tocilizumab for the Treatment of Refractory Behcet's Uveitis
Official title: Efficacy and Safety of Tocilizumab in the Treatment of Refractory Uveitis in Patients With Behcet's Disease
Sponsor: Peking Union Medical College Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated based on its primary and secondary outcome measures in three consecutive patients.
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-10
Primary completion date: 2021-02-01
Completion date: 2021-02-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT01756040: Intestinal Permeability in Preterm Infants
Official title: Gut Permeability in Very Low Birth Weight Infants
Acronym: IPPI
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 211.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-02-01
Primary completion date: 2021-08-31
Completion date: 2021-08-31
Baseline population: The baseline population is the number of infants enrolled in the study.
Plan to share individual participant data: NO
Clinical trial NCT03539601: A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD
Official title: A PHASE 3B/4, MULTICENTER, RANDOMIZED, ASSESSOR BLINDED, VEHICLE AND ACTIVE (TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR) CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY, SAFETY, AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT, 2% IN PEDIATRIC AND ADULT SUBJECTS (AGES 2 YEARS AND OLDER) WITH MILD TO MODERATE ATOPIC DERMATITIS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: This decision was made for business reasons only and is not related to any safety concerns regarding crisaborole.
Enrollment: 237.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-04-27
Primary completion date: 2020-12-11
Completion date: 2020-12-11
Baseline population: Full analysis set (FAS) included all randomized participants received at least 1 dose of investigational product.
Limitations and caveats: Study was terminated early by sponsor. Decision was not due to safety/efficacy concerns, but was related to business, portfolio reprioritization. Sub-study planned as per Amendment 3 was not initiated, as sub study site setup didn't complete prior to study termination.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT05135650: Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
Official title: Pharmacokinetics of a SARS-CoV-2 Monoclonal Antibody in Hematopoietic Stem Cell Transplant Recipients (COVIDMAB)
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Terminated due to FDA withdrawal of the emergency use authorization (EUA) for sotrovimab
Enrollment: 20.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-01-25
Primary completion date: 2022-10-18
Completion date: 2023-01-10
Plan to share individual participant data: NO
Clinical trial NCT01946152: Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
Official title: A Phase I/II Study of Pomalidomide and Dexamethasone With Growth Factor Support in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Per PI at time of CR
Enrollment: 21.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-03-05
Primary completion date: 2020-03-18
Completion date: 2020-03-18
Baseline population: All participants enrolled on the study
Clinical trial NCT04565756: A Study to Evaluate the Safety and Tolerability of EXN407
Official title: A Randomised, Double-Masked Vehicle-Controlled, Multiple Dose, Dose Escalation Study To Evaluate The Safety and Tolerability of EXN407 in Subjects With Centre Involved Diabetic Macular Oedema Secondary to Diabetes Mellitus
Sponsor: Exonate Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 48.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-11-05
Primary completion date: 2022-10-25
Completion date: 2022-11-29
Plan to share individual participant data: NO
Clinical trial NCT05486208: A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis
Official title: A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending Dose Study of LY3844583 in Healthy Participants, and Multiple-Dose Study of LY3844583 in Healthy Participants and Patients With Atopic Dermatitis
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study terminated due to lack of efficacy signal in atopic dermatitis participants.
Enrollment: 102.0 (ACTUAL)
Number of arms: 6.0
Start date: 2022-08-11
Primary completion date: 2024-01-20
Completion date: 2024-01-20
Plan to share individual participant data: NO
Clinical trial NCT04707157: Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain
Official title: Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The trial was slow to enroll, and the sponsor made a business decision to terminate the trial earlier than planned.
Enrollment: 68.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-06
Primary completion date: 2022-06-13
Completion date: 2022-06-13
Baseline population: All enrolled participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03756454: Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.
Official title: A Prospective, Double-blind, Randomized, and Controlled Clinical Trial to Compare the Effectiveness of Intravenous Bezlotoxumab (10 mg/kg) Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant Clostridioides Difficile Requiring Surgical Intervention.
Sponsor: Ohio State University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Difficulties with enrollment and inability to guarantee further study drug supply after current supply expired.
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-19
Primary completion date: 2022-05-23
Completion date: 2022-05-23
Plan to share individual participant data: NO
Clinical trial NCT02102022: Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
Official title: Phase 1/2 Study of ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma
Sponsor: Polaris Group (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Enrollment: 140.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-11-30
Primary completion date: 2020-02-29
Completion date: 2020-02-29
Clinical trial NCT03423264: PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing
Official title: A Phase II Randomized Trial of Prophylactic Gabapentin Plus Best Supportive Care Versus Best Supportive Care Alone for Patients Receiving Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Locoregionally-Advanced, HPV-Related Oropharyngeal Cancer: An Optima II Secondary Study
Sponsor: University of Chicago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: unable to accrue
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-22
Primary completion date: 2022-11-08
Completion date: 2022-11-08
Clinical trial NCT00915681: Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning
Official title: A Phase II Multi-Center Open-Label Clinical Trial to Assess the Prevention of Liver Transplantation and/or Death Among Subjects Treated With Intravenous Silibinin (Legalon® SIL) for Amatoxin Induced Hepatic Failure
Sponsor: Viatris Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 148.0 (ACTUAL)
Number of arms: 1.0
Start date: 2009-11-10
Primary completion date: 2020-04-10
Completion date: 2020-04-10
Baseline population: Study was terminated, no analysis performed as data are unavailable for most patients.
Clinical trial NCT05687617: Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma.
Official title: Diagnostic Value of Intraoperative Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases During Staging Laparoscopy for Gastric Adenocarcinoma: a Prospective, Multicentric Study.
Sponsor: Laval University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Recruitment lower than expected and negative results.
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-12-15
Primary completion date: 2024-03-27
Completion date: 2024-03-27
Plan to share individual participant data: NO
Clinical trial NCT04030598: A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Clinical Efficacy of ISIS 721744, a Second-Generation Ligand-Conjugated Antisense Inhibitor of Prekallikrein, in Patients With Hereditary Angioedema
Sponsor: Ionis Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 23.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-01-07
Primary completion date: 2021-01-04
Completion date: 2021-03-01
Baseline population: The safety population included all enrolled participants who received at least 1 dose of study drug (donidalorsen or placebo).
Plan to share individual participant data: NO
Clinical trial NCT05142228: Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.
Official title: Erenumab as a Therapeutic Approach for the Management of Trigeminal Neuropathic Pain (TNP)
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low enrollment rate
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-31
Primary completion date: 2022-10-27
Completion date: 2022-10-27
Baseline population: Participants who completed baseline period and randomization.
Limitations and caveats: Early termination due to low enrollment rate. Ultimately we only had one participant in only one group.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04355676: Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19
Official title: A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Patients With Moderate or Severe COVID-19
Sponsor: Karyopharm Therapeutics Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-30
Primary completion date: 2020-08-30
Completion date: 2020-08-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03348826: Study of Sodium Bicarbonate in Restoring Blocked Catheters
Official title: Sodium Bicarbonate Injections for Restoration of Flow in a Central Venous Catheter (CVC/Hickman Catheter) or Peripherally Inserted Central Venous Catheter (PICC)
Sponsor: University Health Network, Toronto (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants were enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-01
Primary completion date: 2020-09-01
Completion date: 2021-09-02
Plan to share individual participant data: NO
Clinical trial NCT05242146: GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma
Official title: A Phase 1b/2, Open-label Dose Escalation With Expansion Study of GB5121 in Adult Patients With Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma or Primary Vitreoretinal Lymphoma, With a Phase 2 Open-label Single Dose Level Study of GB5121 in Adult Patients With Relapsed/ Refractory Primary Central Nervous System Lymphoma
Acronym: STAR CNS
Sponsor: Gossamer Bio Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-05-24
Primary completion date: 2023-05-11
Completion date: 2023-05-11
Plan to share individual participant data: NO
Clinical trial NCT02782741: Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease
Official title: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase Alfa in Treatment naïve Patients With Late-onset Pompe Disease
Acronym: COMET
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 101.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-11-02
Primary completion date: 2020-03-19
Completion date: 2023-05-31
Baseline population: Analysis was performed on modified intent-to-treat (mITT) population which included all randomized participants who had received at least 1 infusion (partial or total) and were analyzed according to the treatment arm allocated by randomization.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03448068: Perioperative Ketamine for Pain With Gastric Bypass
Official title: Low-dose Ketamine Infusions for Perioperative Pain Management in Patients Undergoing Laparoscopic Gastric Bypass
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-16
Primary completion date: 2020-01-09
Completion date: 2020-01-09